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Abstract
Background: Early identification of persons with undiagnosed HIV infection is an important health care issue. We examined
associations between diseases diagnosed in hospitals and risk of subsequent HIV diagnosis.
Methods: In this population-based case control study, cases were persons with incident HIV infection diagnosed in
Denmark between 1 January 1995 and 1 June 2008. Risk-set sampling was used to identify 19 age- and gender-matched
population controls for each HIV case, using the HIV diagnosis date as the index date for both cases and controls. Prior
hospital diagnoses obtained from Danish medical databases were first categorized into 22 major disease categories
(excluding AIDS-defining diseases except tuberculosis) and then subdivided into 161 subcategories, allowing us to examine
specific diseases as potential HIV indicators by conditional logistic regression.
Results: The study included 2,036 HIV cases and 35,718 controls. Persons with the following disease categories had a high
risk of HIV diagnosis during the subsequent 5-year period: sexually transmitted infections and viral hepatitis (adjusted odds
ratio [aOR]=12.3, 95% CI: 9.60–15.7), hematological diseases (aOR=4.28, 3.13–5.85), lower respiratory tract infections
(aOR=3.98, 3.14–5.04)), CNS infections (aOR=3.44, 1.74–6.80), skin infections (aOR=3.05, 2.47–3.75), other infections
(aOR=4.64, 3.89–5.54), and substance abuse (aOR=2.60, 2.06–3.29). Several specific diseases were associated with aORs
.20 including syphilis, hepatitis A, non ‘‘A’’ viral hepatitis, herpes zoster, candida infection, endocarditis, thrombocytopenia,
and opioid abuse.
Conclusions: Targeted testing for HIV in patients diagnosed with diseases associated with HIV may lead to earlier treatment
and thereby reduced morbidity, mortality and HIV transmission.
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Introduction
Despite three decades of concerted effort, the HIV epidemic
remains a tremendous public health challenge in both low- and
high-income countries [1,2]. Many individuals newly diagnosed
with HIV present at a late stage of the disease with severe immune
depletion, resulting in delayed initiation of antiretroviral therapy
(ART) which worsens their prognosis [3] and increases further
transmission of HIV [4,5,6]. Recently, the European Center for
Disease Control and Prevention’s Dublin Declaration Progress
Report 2010 concluded that ‘‘the rates of late diagnosis remain
unacceptably high’’ in Europe and Central Asia [7]. Thus,
intensified HIV testing and treatment has been advocated to lower
the prevalence of undiagnosed HIV infection and to control the
HIV epidemic [8,9].
The U.S. Centers for Disease Control and Prevention (CDC)
recommend routine HIV testing for all persons under age 65 who
come into contact with the health care system [10]. While this
approach may be cost-effective in areas with high HIV prevalence
[11] and does prolong life expectancy [3], alternative approaches
such as targeted HIV testing may be more appropriate in other
settings with lower HIV prevalence or different health care systems
[2].
Targeted HIV testing based on risk groups (e.g. injecting drug
users [IDU] [12]), presence of AIDS-defining illnesses, or coming
from a high-HIV prevalence country is practised in most
PLoS ONE | www.plosone.org 1 March 2012 | Volume 7 | Issue 3 | e32538European countries [13]. However, many opportunities for HIV
testing are missed by the health care system prior to HIV diagnosis
[14]. In 2007, the pan-European initiative ‘‘HIV in Europe’’
recommended that targeted testing based on the presence of
diseases associated with HIV, so-called indicator diseases [15],
should be developed as an additional tool to guide targeted HIV
testing. HIV indicator diseases may be a result of individual risk
behavior or coexisting HIV infection. Several studies have
identified indicator diseases within a narrow spectrum of
conditions [16,17,18,19], but to date there has been no
comprehensive study of HIV indicator diseases. In the absence
of adequate data, guidance is based mainly on expert opinion [15].
There is substantial information regarding the prevalence of
indicator diseases in the HIV-infected population. In contrast, the
relative risk of HIV among patients with indicator diseases remains
poorly described. The goal of this study was to delineate medical
conditions that identify individuals at increased risk of subsequent
HIV diagnosis.
Methods
Ethics statement
The Danish Data Protection Agency approved the establish-
ment of the cohort and the linkage between the four registries in
this study (J.-no. 2008-41-1781). The study was not subject to
approval by the ethics committee because data collection did not
involve direct patient contact and all data was fully de-identified.
We conducted a population-based nested case control study
among persons with and without an incident HIV diagnosis in
Denmark. The adult population of Denmark is 4.3 million with an
estimated HIV infection prevalence of 0.09% [20]. The Danish
healthcare system provides free, tax-supported medical care for all
residents, including antiretroviral treatment of HIV.
Data sources
The civil registration system (CRS) number, assigned at birth,
uniquely identifies each person living in Denmark since 1968 and
is used for personal identification in all Danish administrative and
medical databases. We used this unique 10-digit CRS-number to
link data among the following registries: The Danish HIV Cohort
Study (DHCS) is a prospective, open, nationwide, population-based
cohort of all HIV-infected individuals receiving care in Danish
HIV clinics since 1 January 1995 [20]. The study is ongoing, with
continuous enrolment of newly diagnosed patients. The Danish Civil
Registration System records demographic information, vital status,
and immigration and emigration dates for all Danish citizens
beginning in 1967 [21]. The Danish National Registry of Patients
(DNRP) contains information on all patients discharged from
Danish hospitals since 1977 [22]. It includes diagnoses coded by
the treating physician according to the International Classification of
Diseases, 8th revision (ICD-8) up to the end of 1993 and according
to the 10th revision (ICD-10) thereafter. The registry covers public
as well as private hospitals and so constitutes a virtually complete
population-based database. The Danish Cancer Registry (DCR) has
recorded all incident cancers in Denmark since 1943, classifying
cancers registered after 1977 according to ICD-10 [23].
Study population
Cases. Cases were identified from DHCS and included all
individuals who (I) were diagnosed with HIV between 1 January
1995 and 1 June 2008; (II) were at least 16 years of age on the date
of HIV diagnosis; and (III) were living in Denmark for at least 5
years prior to HIV diagnosis. The index date for HIV cases was
defined as the date of first positive HIV test as registered in the
DHCS.
Population controls. Controls not diagnosed with HIV were
identified from the CRS using incidence density sampling, which
involves matching each case to a sample of those who are at risk at
the time of case occurrence [24]. To ensure sufficient statistical
power to detect differences in the occurrence of rare events, we
sampled for each case 19 random age- and gender-matched
population controls that were alive on the HIV diagnosis date of
their respective case. The date of HIV diagnosis/sampling
constituted the index date for both cases and controls. Controls
who, according to the CRS, had not been living in Denmark for at
least 5 years prior to the index date were excluded. Hence, all
study subjects were living in Denmark during the 5-year period
prior to their index date and therefore at risk of both exposure and
outcome.
Identification of hospital diagnoses and grouping of
disease categories
For all study subjects we extracted hospital diagnoses from
outpatient contacts and hospital stays from the DNRP and DCR,
up to the day prior to the index date. ICD-10 codes were the
primary source for grouping diseases. We defined 22 disease
categories of interest according to the type and anatomical
location of the disease (Table S1). ICD-8 codes were translated to
the corresponding ICD-10 disease categories and first-time
diagnoses were assigned to the appropriate category. In addition,
a total of 161 subcategories were created for the 22 disease
categories, allowing us to examine specific diseases as potential
HIV indicators (Table S1). Except for tuberculosis, we excluded
AIDS-defining diseases, because their association with HIV
infection is well established [25].
Statistical analyses
For cases and controls, we tabulated gender, age (16–39 years,
40–49 years, 50–59 years, and 60+ years), and hospital contact(s)
in the 5-year period prior to the index date for each of the 22
disease categories (yes/no). For cases, the following variables were
also included: race, most likely mode of HIV acquisition, presence
of AIDS [25] at diagnosis, first CD4
+ cell count, and HIV RNA
measurement (within 180 days of HIV diagnosis). Frequencies and
percentages were computed for all variables.
Conditional logistic regression analyses
For each of the 22 disease categories, conditional logistic
regression analysis was used to estimate odds ratios (OR), which is
an unbiased estimate of the incidence rate ratio (IRR) for
subsequent HIV diagnosis [24]; unadjusted ORs as well as ORs
adjusted for the remaining 21 disease categories were estimated.
Observation data were subsequently stratified into three time
periods prior to the index date (less than 1 year, 1–2 years, and 3–
5 years,) to explore changes in ORs in the years following a given
disease or disease category. We used first-time diagnoses
registered within each time stratum for a given disease/disease
category. Adjusted ORs were calculated for each disease category
and time period (adjusted for the remaining 21 disease
categories). To identify specific HIV-indicator diseases, we
explored risk estimates for the 161 specific subcategories within
each of the 22 disease categories. We computed both unadjusted
odds ratios for each subcategory and odds ratios adjusted for
other diseases within the same disease category (Table S1). In all
analyses, only first-time diagnoses for a given disease/disease
category were utilized.
Indicator Diseases for HIV Infection
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We identified 2,363 individuals diagnosed with HIV between 1
January 1995 and 1 June 2008 and 38,684 controls. Of these, 327
cases and 2,966 controls were excluded because they immigrated
to Denmark less than 5 years prior to their index date. Thus, a
total of 2,036 cases and 35,718 controls were included resulting in
an average of 17.5 controls per case.
In the 5 years prior to their index date, there were a total of
138,416 hospital contacts for both cases and controls, of which
34,520 represented a first-time diagnosis for one of the 22 disease
categories. Table 1 shows characteristics of cases and controls on
their index date. In the 5 years preceding the index date, 69.8% of
cases (1,421 of 2,036 cases) and 53.6% of controls (19,148 of
35,718 controls) had at least one hospital contact for one of the 22
disease categories delineated below.
Disease category and risk of subsequent HIV diagnosis
Several disease categories were associated with an increased risk
of HIV diagnosis during the following 5-year period (Figure 1).
Persons diagnosed a disease in the category ‘‘sexually transmitted
infections (STIs) and viral hepatitis’’ had the highest risk of
subsequent HIV diagnosis (adjusted OR [aOR]=12.3, 95%
confidence interval [CI], 9.60–15.7). Also persons with infections
(lower respiratory tract infections, CNS infections, skin infections,
and other infections), hematological diseases, non-AIDS defining
cancers, substance abuse, poisoning, ear, nose, and throat diseases,
skin diseases, and gastrointestinal diseases had higher risk of HIV
diagnosis during the following 5 years. Seven disease categories
were not associated with subsequent HIV diagnosis: eye diseases,
kidney diseases, lung diseases, ischemic heart disease (IHD), non-
IHD vascular diseases, neurological diseases, and trauma. A
decreased risk of subsequent HIV diagnosis was found for persons
with rheumatological diseases (aOR=0.72, 95% CI:0.62–0.85),
non-diabetes endocrine diseases (aOR=0.60, 95% CI:0.42–0.86),
and diabetes (aOR=0.40, 95% CI:0.23–0.69).
Time trends in risk of HIV diagnosis following hospital
contact
Figure 2 shows the relative risk of subsequent HIV in 3 time
periods: ,1 year, 2–3 years, and 3–5 years after each of the 22
disease categories. The time trends can be categorized in four
main groups: 1) no time trend (eye diseases, lung diseases, kidney
diseases, IHD, neurological diseases, trauma, rheumatological
diseases, non-diabetic endocrine diseases, and diabetes); 2) A
highly increased risk of HIV in the first year after diagnosis and no
or only a slightly increased risk thereafter (hematological diseases,
non-AIDS malignancy, skin diseases, gastrointestinal diseases, and
non-IHD vascular diseases); 3) gradually decreased risk of HIV
over time (lower respiratory tract infections, CNS infections, skin
infections, other infections, and ear, nose, and throat diseases); 4)
persistently increased risk both in the short and the long term
(STIs and viral hepatitis, substance abuse, and poisoning).
Specific HIV-indicator diseases
To determine whether any specific diseases were strong
indicators of subsequent HIV diagnosis, we further divided the
22 disease categories into 161 subcategories. Table 2 reports risk
estimates for subcategories associated with at least a 3-fold elevated
risk of subsequent HIV diagnosis (all 161 subcategories shown in
Table S2). We found strong associations between all groups of
STIs and viral hepatitis and subsequent HIV diagnosis. Several
other specific groups of infectious diseases, including meningitis,
herpes zoster, endocarditis, and malaria, were closely associated
with later HIV diagnosis. Among hematological diseases and
cancers: thrombocytopenia, anemia, lymphadenitis, non-AIDS
defining lymphomas, and secondary and unspecified malignant
neoplasm of lymph nodes were associated with later HIV
diagnosis. Genital cancers were not. In the group of gastrointes-
tinal diseases, diseases of the oral cavity, liver diseases, and
fissures/abscesses of the anal cavity were strongly associated with
Table 1. Baseline characteristics
a of HIV cases and HIV-
uninfected controls.
Cases Controls
(n=2,036) (n=35,718)
Sex, n (%)
Female 380 (18.7) 6,555 (18.4)
Male 1,656 (81.3) 30,819 (81.6)
Age at diagnosis, n (%)
16–39 years 1,122 (55.1) 18,899 (52.91)
40–49 years 510 (25.1) 9,266 (25.9)
50–59 years 290 (14.2) 5,410 (15.2)
60+ years 114 (5.6) 2,143 (6.0)
Hospital contact, n (%)
b
Yes 1,421(69.8) 19,148 (53.6)
No 615 (30.2) 16,570 (46.4)
Race, n (%)
Caucasian 1,798 (88.7) –
Black 119 (5.9) –
Asian 55 (2.7) –
Inuit 19 (0.9) –
Other 36 (1.8) –
Mode of HIV exposure, n (%)
MSM 975 (47.9) –
Heterosexual 722 (35.5) –
IDU 210 (10.3) –
Other 49 (2.4) –
Unknown 80 (3.9) –
AIDS at diagnosis, n (%)
No 1,847 (90.7) –
Yes 189 (9.3) –
First CD4
+ count (cells/mL)
c
,350 999 (49.1) –
$350 829 (40.7) –
missing 208 (10.2)
First HIV RNA measurement (copies/mL)
c
#10
4 343 (16.9) –
.10
4 & #10
5 622 (30.6) –
.10
5 660 (32.4) –
missing 411 (20.2)
aBaseline was defined as the index date which was the date of HIV diagnosis for
cases and their corresponding controls (matched on the day the case was
diagnosed with HIV).
bIn the 5 years prior to the index date for at least one of the 22 disease
categories in Table S1.
cWithin 180 days of HIV diagnosis. The table shows data on HIV cases and HIV-
uninfected controls with at least 5 years of continuous observation prior to the
index date. MSM, men who have sex with men; IDU, injection drug use.
doi:10.1371/journal.pone.0032538.t001
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was associated with increased risk of HIV diagnosis. Ischemic
heart disease, including myocardial infarction (aOR=0.81,
95%:0.39–1.69) and other cardiovascular diseases, were not
associated with later HIV diagnosis, with the notable exception
of thrombophlebitis (aOR=5.29, 95% CI:3.51–7.96).
Among fourteen individuals diagnosed with hepatitis A
infection, 12 (85.7%) were men who had sex with men (MSM).
Five (50%) of ten cases with malaria were non-Caucasian
immigrants. In 62 of 68 cases (91.2%) with opioid abuse-related
diagnoses, IDU was registered as the mode of HIV transmission.
First-time diagnoses for the 52 diseases in Table 2 represented
3,257 (1.9%) of all 138,416 hospital contacts registered in the 5
years prior to the index date. In the HIV cohort of 2,036
individuals, 782 (38.4%) had at least one hospital contact for an
indicator disease, while this occurred for only 2,475 (6.9%) of
35,718 controls. For the 1,826 cases not reporting IDU as mode of
HIV infection, 613 (34.1%) had a first-time hospital contact for
diseases listed in Table 2.
Discussion
We found that HIV indicator diseases identified over one-third
of all individuals who would become diagnosed with HIV in the
subsequent 5-year period. Recognition of these HIV indicator
diseases could aid healthcare personnel in identifying individuals at
increased risk of undiagnosed HIV. The time-dependent associ-
ation between the date of diagnosis of some disease categories and
HIV diagnosis suggests that for several categories repeated (e.g.
yearly) HIV testing is advisable.
To our knowledge, this is the first population-based study
conducted to identify HIV indicator diseases across all disease
categories. While some indicator diseases we identified were
previously recognized [15,16,17,26], the size of our study
population and completeness of hospitalization data allowed us
to provide risk estimates with high statistical precision for the
majority of disease groups. Our results thus can be used to guide
strategies for targeted HIV testing in the hospital settings.
Figure 1. Association between subsequent risk of HIV diagnosis and hospital contact for 22 major disease categories.
doi:10.1371/journal.pone.0032538.g001
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HIV cohort studies, an unknown proportion of people with HIV
may have died without being diagnosed with the condition. Thus,
we may have underestimated the relative risk of subsequent HIV
diagnosis after life-threatening conditions such as cancer [26].
Additionally, we had access only to hospital diagnoses, which may
have caused us to underestimate the occurrence of diseases
diagnosed outside the hospital system, such as syphilis, fungal skin
infections, and herpes zoster. If patients at risk of HIV are more
prone to be diagnosed in a hospital setting this will lead to a
potential overestimation of the predictive value of some HIV
predictor diseases if compared with those from a non-hospital
setting. Another potential shortcoming is inaccuracies in diagnoses
reported to national hospital databases. However, the positive
predictive value of registry diagnoses (i.e. the proportion of
subjects with a given registry diagnosis which is correct when
compared to medical records) is generally high (70%–99%)
[22,27]. Furthermore, risk of subsequent HIV diagnosis may be
elevated if a given disease diagnosis increases the likelihood of HIV
testing, regardless of its actual association with HIV infection. This
phenomenon would produce a close association between the
timing of the disease and HIV diagnoses. Although persons with
some disease categories had increased risk of HIV in the first year
thereafter (Figure 2), the increased risk of subsequent HIV
diagnosis was also observed more than 1 year after the disease.
Hence, this phenomenon could only have a moderate effect on the
5-year estimates. Finally, it should be noted that due to our use of
hospital diagnoses, we were unable to identify clinical features that
may further enhance the predictive value of given indicator
diseases (e.g. ‘‘florid or hard to treat’’ fungal skin infection).
HIV indicator diseases can be grouped into three major types.
First, disease manifestations of acute HIV infection (e.g. acute viral
Figure 2. Association between risk of subsequent HIV diagnosis and time of hospital contact.
doi:10.1371/journal.pone.0032538.g002
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subsequent HIV diagnosis.
Disease category Specific disease
Cases
n=2,036
Controls
n=35,718 aOR (95% CI)
a
Infections
STIs and viral hepatitis Syphilis 15 2 94.7 (20.9–429)
STIs and viral hepatitis Hepatitis A 14 4 41.6 (11.7–148)
STIs and viral hepatitis Non ‘‘A’’ viral hepatitis
b 77 55 23.6 (16.5–33.7)
STIs and viral hepatitis Anogenital herpes simplex 7 10 12.7 (4.65–34.8)
STIs and viral hepatitis Condyloma 55 95 8.99 (6.32–12.8)
STIs and viral hepatitis Other STIs 18 12 14.8 (6.35–34.6)
Lower respiratory tract infections Unspecified pneumonia 126 290 7.56 (6.03–9.48)
Lower respiratory tract infections Pneumococcal pneumonia 9 14 4.33 (1.63–11.5)
Lower respiratory tract infections Influenza and viral pneumonia 9 43 3.21 (1.51–6.81)
CNS infections Bacterial meningitis 5 9 14.7 (5.63–38.1)
CNS infections Viral meningitis or encephalitis 9 25 6.33 (2.90–13.8)
CNS infections Other CNS infections 9 10 5.51 (1.60–19.0)
Skin infections Abscess, furuncle, carbuncle 137 409 5.15 (4.17–6.35)
Skin infections Fungal skin infections 3 11 4.41 (1.18–16.5)
Skin infections Erysipelas 25 76 3.92 (2.39–6.45)
Skin infections Other skin infections 45 95 5.29 (3.56–7.86)
Other infections Herpes zoster 22 8 33.7 (14.3–79.6)
Other infections Candida infection
c 40 22 25.5 (14.6–44.6)
Other infections Endocarditis 11 7 23.2 (8.71–61.9)
Other infections Tuberculosis and other mycobacterial infections 24 21 15.2 (7.99–29.1)
Other infections Malaria 10 12 9.53 (3.86–23.5)
Other infections Mononucleosis 11 19 8.64 (4.04–18.5)
Other infections Lymphangitis 5 8 7.88 (2.40–25.9)
Other infections Unspecified viral illness 23 44 7.87 (4.56–13.6)
Other infections Sepsis 23 34 4.90 (2.52–9.52)
Other infections Infectious gastroenteritis 50 216 3.48 (2.49–4.87)
Other infections Other types of infection 67 182 4.77 (3.46–6.56)
Hematological diseases and cancers
Hematological diseases Thrombocytopenia 15 10 24.0 (10.5–54.7)
Hematological diseases Unspecified anemia 24 44 7.26 (4.19–12.6)
Hematological diseases Lymphoma 18 43 5.83 (3.22–10.5)
Hematological diseases Aplastic and other specified anemias 7 17 4.58 (2.38–8.79)
Hematological diseases Lymphadenitis 13 42 3.44 (1.42–8.30)
Hematological diseases Nutrition deficiency anemia 7 27 3.11 (1.11–8.70)
Hematological diseases Other hematological diseases 5 18 4.30 (1.54–12.0)
Non-AIDS defining cancers Secondary and unspec. malignant neoplasm of lymph nodes 11 22 6.74 (3.14–14.5)
Substance abuse and poisoning
Substance abuse Substance abuse opioids 69 17 43.5 (24.6–76.8)
Substance abuse Substance abuse other 51 55 6.54 (4.07–10.5)
Drug poisoning Narcotics and hallucinogens 47 43 11.2 (7.08–17.8)
Other disease categories
Ear, nose, and throat diseases Other acute upper respiratory tract infection 10 30 5.02 (2.38–10.6)
Ear, nose, and throat diseases Chronic disease of tonsils and adenoids 43 129 4.95 (3.45–7.09)
Skin diseases Seborrhoeic dermatitis 9 8 11.8 (4.30–32.6)
Gastrointestinal diseases Fissure/abscess of anal and rectal regions 50 202 4.35 (2.87–6.61)
Gastrointestinal diseases Liver diseases 31 103 4.06 (2.27–7.25)
Gastrointestinal diseases Disease of salivary glands, oral mucosa, tongue and lips 15 58 3.97 (2.88–5.48)
Indicator Diseases for HIV Infection
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ing HIV infection (e.g. herpes zoster or thrombocytopenia); and
third, diseases associated with behavior that increases the risk of
acquiring HIV (e.g. hepatitis and opioid abuse). The latter group is
highlighted in Figure 2, which shows that disease categories related
to individual risk behaviors (e.g. STIs and viral hepatitis) are
associated with an elevated risk that remained constant over time.
Other disease categories which may be related to coexisting HIV,
such as respiratory infections, hematological diseases, and non-
AIDS-defining cancers, showed a highly increased risk of HIV in
the first year after the diagnosis. The close connection between the
date of hospital contact and date of HIV diagnosis suggests that
the hospital contacts led to subsequent HIV testing as part of the
recommended medical work-up (e.g. following lymphoma diag-
nosis) [15]. Among specific HIV indicator diseases, acute hepatitis
A virus (HAV) infection was associated with high risk of
subsequent HIV diagnosis. The strong association between acute
HAV infection and MSM suggests that HAV infection is a proxy
for high-risk sexual behavior in our study population [28]. Our
data also indicate that endocrine and rheumatological diseases
(except infectious arthropathy) are associated with decreased risk
of HIV which may be related to low-risk sexual behavior among
individuals with these chronic diseases [29]. Factors associated
with a specific behaviour or transmission risk (such as MSM, IDU,
and migration) may represent potential confounders. Information
on these risk factors were not available for controls and thus, could
not be adjusted for in the analyses. However, the purpose of the
present study was to identify indicator diseases regardless of their
causal or non-causal relationship to HIV infection. Therefore, our
estimates represent the risk of a given disease compared to a
representative sample of a background population of mixed race
and sexual orientation. Our study only included first-time
diagnosis and we did not assess the effect of repetitively diagnoses
(e.g. pneumonia). Repetitive diagnoses of indicator diseases in an
individual is most likely associated with even higher risk of
undiagnosed HIV, and thus should prompt immediate HIV
testing.
Targeted HIV testing is practiced in many countries [2,13,15]
and may be more cost-effective than universal HIV testing in low
HIV prevalence regions like Denmark [30,31]. However, until
now the lack of a thorough delineation of HIV indicator diseases
has markedly reduced the efficacy of targeted HIV testing [2].
Another barrier to HIV screening is the acceptance of testing
among patients [32]. While the acceptance of universal opt-out
HIV testing among emergency department patients has varied
greatly [33,34] and was as low as 24% in a recent trial [35],
physician recommended HIV testing is more acceptable for most
patients [32]. Thus, expanding targeted HIV testing using
indicator diseases may be an agreeable approach for patients. In
our study, HIV indicator diseases could potentially detect
approximately two out of every five persons with HIV at an
earlier stage. If the earlier diagnosis leads to earlier ART initiation,
indicator disease-based HIV screening has the potential to reduce
both HIV-related morbidity and HIV transmission [36,37,38].
This screening strategy should of course be added to the usual
HIV screening initiatives to ensure un-delayed diagnosis of the
remaining 60% of persons with HIV. Almost one-third of cases in
our study had no hospital contacts in the 5 years prior to their HIV
diagnosis. Therefore, national screening initiatives could aim to
expand current non-hospital based strategies such as community
outreach programs aimed at high-risk groups (e.g. sex workers and
drug users) [39,40].
In conclusion, knowledge of HIV indicator diseases may
optimize national HIV testing programs but the effectiveness of
indicator disease-based HIV screening needs confirmation in
clinical studies. Although the use of indicator diseases may
enhance the identification of undiagnosed HIV-infected individ-
uals, this strategy can only be supplementary to systematic HIV
testing of risk groups identified through information about their
behavioral risk-taking profiles.
Supporting Information
Table S1 International Classification of Diseases, version 8 and
version 10 codes used for the analyses.
(XLS)
Table S2 Section 1 to 22 contains information and risk estimates
on subcategorized disease groups for each of the 22 major disease
categories. First-time diagnoses within each disease group were
recorded if occurring less than 5 years prior to index date.
Unadjusted odds ratio [OR] and adjusted odds ratio [aOR] for all
other variables within the same disease category are shown with
Disease category Specific disease
Cases
n=2,036
Controls
n=35,718 aOR (95% CI)
a
Lung diseases Respiratory disease principally affecting the interstitium 7 13 9.22 (3.63–23.4)
Lung diseases Lung abscess/empyema without pneumonia 5 11 6.42 (2.16–19.1)
Lung diseases Pneumothorax 8 40 3.25 (1.98–5.35)
Lung diseases Other lung diseases 21 95 3.00 (1.37–6.55)
Non-IHD vascular diseases Thrombophlebitis 34 106 5.29 (3.51–7.96)
Neurological diseases Facial nerve disorder 8 31 3.04 (1.46–6.35)
Neurological diseases Polyneuropathy 9 47 4.52 (2.07–9.85)
Rheumatological diseases Infectious arthropathy 14 75 3.18 (1.76–5.74)
aAdjusted for other diseases within the same disease category (Table S1).
bDiagnosis of non-A hepatitis coded by ICD-10 were evenly distributed between hepatitis B and C with no significant difference in their association to risk of subsequent
HIV diagnosis.
cThe subcategory candida infection primarily consisted of ‘‘oral candidiasis’’ but other types of candidiasis also occurred albeit at too low frequencies to be analyzed
seperately. Risk estimates for all 161 subcategories are shown in Table S2. aOR, adjusted odds ratio; CI, confidence interval; STIs, sexually transmitted infections; IHD,
ischemic heart disease.
doi:10.1371/journal.pone.0032538.t002
Table 2. Cont.
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analyses were: Cases (n=2,036) and controls (n=35,718).
(XLS)
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